U.S. Affiliate of Growing International Pharmaceutical Organization Signs Agreement with eResearchTechnology Totaling More Than
11 March 2004 - 1:01AM
PR Newswire (US)
U.S. Affiliate of Growing International Pharmaceutical Organization
Signs Agreement with eResearchTechnology Totaling More Than $1.1
Million for Cardiac Safety Monitoring and Information Distribution
Services Study Targets Novel Therapy in Late Phase Development
PHILADELPHIA, March 10 /PRNewswire-FirstCall/ --
eResearchTechnology, Inc. (eRT) , a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has received an agreement for more than
$1.1 million in cardiac safety monitoring and services from the
U.S. affiliate of a growing international pharmaceutical
organization for one of its drug candidates in late phase clinical
development. The agreement covers a significant Phase III study
that will be conducted at 70 sites in the U.S. and Canada. eRT will
provide comprehensive support and 70 units of 12-lead ECG equipment
designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis.eRT will perform digital
collection, measurement, interpretation, review, and distribution
of cardiac safety data through its EXPeRT workflow enabled data
handling technology, the first solution in production that was
designed explicitly to meet emerging international regulatory
guidance and technical standards. "We are pleased to have been
awarded this study, which illustrates the effect that emerging
international standards for cardiac safety in new drug development
are having on clinical research across all phases," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "Extensive overall testing in target
patient populations and more robust cardiac safety profiling are
combining to drive increasingly large scale digital cardiac safety
collection, management, analysis, and distribution requirements
from pharmaceutical and biotechnology organizations across all
geographies and segments." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The sponsor
may cancel these agreements at its sole discretion. As a result,
actual results may differ materially from any financial outlooks
stated herein. Further information on potential factors that could
affectthe company's financial results can be found in the company's
Reports on Forms 10-K and 10-Q filed with the Securities and
Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT:
Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-760-487-1137, for
eResearchTechnology Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles